# Pediatric Croup Treatment

Treat croup severity at the bedside: give single-dose dexamethasone for children seeking care, add nebulized epinephrine for stridor at rest or increased work of breathing, observe after epinephrine, and escalate promptly when hypoxemia, exhaustion, or poor response suggests impending airway failure.

**Clinical question:** How should dexamethasone and nebulized epinephrine be selected, dosed, observed, and escalated for children with croup?

Updated: 2026-09-15T21:34:15.911960+00:00

## What matters in practice
- Give a single dose of dexamethasone to children presenting for care with croup, including mild disease; oral administration is preferred when tolerated. [2][4][18]
- Use nebulized epinephrine for moderate-to-severe croup, particularly stridor at rest with retractions or decreased air entry; it produces rapid but transient improvement. [5][6][20][24]
- Racemic epinephrine 2.25% 0.5 mL in 2.5 mL saline and L-epinephrine 1:1,000 5 mL are accepted alternatives; comparative evidence does not favor one formulation. [5][23][24]
- Observe after epinephrine because its clinical effect lasts about 1-2 hours; discharge requires sustained improvement without stridor at rest. [5][6][14][18]
- Hypoxemia in croup indicates severe upper-airway obstruction with possible impending respiratory failure and warrants oxygen, airway-focused escalation, and admission-level monitoring. [6][15]

## Identify children needing immediate airway-focused escalation

Severity determines whether corticosteroid alone is sufficient or epinephrine and monitored care are required.

Classify illness clinically before treatment: mild croup has stridor without intercostal retractions, whereas moderate-to-severe disease includes increased work of breathing. Stridor at rest, chest-wall indrawing, biphasic stridor, decreased air entry, or hypoxia should move management from outpatient steroid treatment to nebulized epinephrine plus observation. [6][20]

Give supplemental oxygen for diminished oxygen saturation. In croup, hypoxemia is not a routine feature of uncomplicated upper-airway disease; it signals severe obstruction and possible impending respiratory failure. A child with hypoxia, markedly decreased air entry, escalating fatigue, or inadequate response to repeated epinephrine requires admission-level monitoring and consideration of intensive care support. [5][6][15]

Reconsider the diagnosis rather than repeatedly treating presumed viral croup when the presentation is atypical or deterioration is disproportionate. Important alternatives include bacterial tracheitis, epiglottitis, foreign-body aspiration, peritonsillar abscess, retropharyngeal abscess, and angioedema. [4]
- Mild: no stridor at rest; administer dexamethasone and plan discharge if the child remains clinically stable. [15][18]
- Moderate: stridor at rest with retractions/chest-wall indrawing; administer dexamethasone plus nebulized epinephrine and observe response. [5][6][15]
- Severe or failing therapy: give dexamethasone and nebulized epinephrine, repeat epinephrine if needed, and arrange inpatient or intensive care support when response is insufficient. [5][15]

*Bedside severity-based treatment and disposition framework for pediatric croup. [5][6][15][20]*

| Clinical branch | Bedside findings | Immediate treatment | Next disposition decision |
| --- | --- | --- | --- |
| Mild croup | Stridor without intercostal retractions; no stridor at rest. [20] | Single-dose dexamethasone, preferably oral if tolerated. [4][18] | Discharge when stable with no stridor at rest. [18] |
| Moderate croup | Stridor at rest with chest-wall indrawing or increased work of breathing. [5][20] | Dexamethasone plus nebulized epinephrine. [5][15] | Observe after epinephrine; admit if improvement is insufficient after 4-6 hours following corticosteroid administration. [5] |
| Severe croup or impending respiratory failure | Marked obstruction, poor air entry, hypoxia, or persistent symptoms after repeated epinephrine. [6][15] | Oxygen for low saturation; dexamethasone and nebulized epinephrine; repeat epinephrine when necessary. [5][15] | Extended observation or admission; consider intensive care support if response remains inadequate. [5][15] |

## Use single-dose dexamethasone across the severity spectrum

Dexamethasone changes the disease course; epinephrine provides short-term relief while corticosteroid benefit develops.

Administer dexamethasone once to children who present for medical care with croup, including mild disease. In mild croup, a single oral dose produced small but clinically important clinical and economic benefits. Across croup severity, corticosteroid treatment reduces symptoms, subsequent treatments, hospitalization-related outcomes, and return visits. [2][4][18][21]

A commonly used dexamethasone regimen is 0.6 mg/kg once, maximum 10 mg, administered orally, intramuscularly, or intravenously; choose oral therapy when the child can take it. In moderate outpatient croup, a single oral dose was not inferior to intramuscular dosing for subsequent intervention in one study. Reserve intramuscular or intravenous administration for vomiting, inability to tolerate oral medication, or severe respiratory distress. [17][18][21]

Dose selection remains a practical area of variation. Doses of 0.15-0.6 mg/kg are described in treatment algorithms, and randomized hospitalized-croup data found 0.15 mg/kg orally comparable with 0.3 and 0.6 mg/kg for symptom outcomes, hospitalization duration, epinephrine use, intensive care use, and recurrence-related care. When an institutional pathway specifies 0.6 mg/kg, that regimen has the broadest historic use; lower-dose regimens are supported by comparative trial data. [4][18][20][22]
- Preferred route: oral dexamethasone when tolerated. [17][18][19]
- Common regimen: dexamethasone 0.6 mg/kg once by mouth, IM, or IV; maximum 10 mg. [18]
- Alternative evidence-supported dose range: dexamethasone 0.15-0.6 mg/kg once. [4][20][22]
- Do not substitute humidification or cool mist for pharmacotherapy; published evidence does not support these interventions. [4][20]

### When nebulized budesonide is useful

Use nebulized budesonide 2 mg as an alternative when oral dexamethasone is not tolerated. Budesonide improves symptoms compared with placebo and has shown efficacy similar to dexamethasone in moderately severe croup, but oral corticosteroid administration is generally preferred when feasible because it is more convenient and less expensive. [1][3][18][19][20]

*Corticosteroid options for children presenting with croup. [4][17][18][20][22]*

| Option | Dose and route | Use case | Decision point |
| --- | --- | --- | --- |
| Dexamethasone | 0.6 mg/kg once PO, IM, or IV; maximum 10 mg. [18] | Children with croup of any severity presenting for care. [2][4][18] | Use PO when tolerated; use IM/IV if oral administration is not feasible. [17][21] |
| Lower-dose dexamethasone | 0.15-0.3 mg/kg once PO. [20][22] | Institutional pathways or clinicians using lower-dose protocols. [20][22] | A 0.15 mg/kg dose had comparable trial outcomes to 0.3 and 0.6 mg/kg in hospitalized children. [22] |
| Nebulized budesonide | 2 mg by nebulizer. [18][20] | Child unable to tolerate oral dexamethasone. [20] | Use as an alternative rather than routine addition to tolerated oral dexamethasone. [19][20] |

## Add nebulized epinephrine for stridor at rest or significant work of breathing

Epinephrine is a temporizing treatment for clinically important upper-airway obstruction, not a replacement for dexamethasone.

For moderate-to-severe croup, administer nebulized epinephrine together with dexamethasone. Appropriate triggers include stridor at rest, retractions, biphasic stridor, decreased air entry, or hypoxia. Nebulized epinephrine improves croup scores within 30 minutes versus placebo, but does not alter the underlying disease course. [6][15][20][24]

Use either racemic epinephrine 2.25%, 0.5 mL diluted in 2.5 mL normal saline, or L-epinephrine 1:1,000, 5 mL by nebulizer. Weight-based regimens described for smaller children are racemic epinephrine 0.05 mL/kg of 2.25% solution to a maximum of 0.5 mL, or L-epinephrine 0.5 mL/kg of 1:1,000 solution to a maximum of 5 mL. Available comparative evidence does not favor racemic over L-epinephrine. [5][16][23][24]

Expect benefit to be transient: the effect generally lasts 1-2 hours. Pallor and tachycardia are usually mild and transient, but the clinically important safety issue is recurrence of obstruction as the medication effect wanes. Repeat nebulized epinephrine for persistent severe symptoms while arranging higher-acuity care if response remains inadequate. [5][6]
- Do not use epinephrine routinely for mild croup without stridor at rest. [15][23]
- Give dexamethasone concurrently because epinephrine is short acting and dexamethasone has a longer duration of action. [16]
- Persistent symptoms after 2 or more racemic epinephrine doses should prompt extended observation or hospital admission. [15]

*Nebulized epinephrine formulations and monitoring implications. [5][6][16][23][24]*

| Formulation | Nebulized dose | Expected role | Observation implication |
| --- | --- | --- | --- |
| Racemic epinephrine | 2.25% 0.5 mL in 2.5 mL saline; alternatively 0.05 mL/kg, maximum 0.5 mL. [5][16][23] | Rapid treatment for moderate-to-severe croup. [6][15] | Observe for recurrence as effect wanes after approximately 1-2 hours. [5][6] |
| L-epinephrine | 1:1,000, 5 mL; alternatively 0.5 mL/kg, maximum 5 mL. [5][16][23] | Accepted alternative when racemic epinephrine is unavailable. [5][24] | Use the same post-treatment monitoring approach because comparative evidence does not favor either formulation. [24] |

## Observe after epinephrine and admit for persistent obstruction

Disposition should be based on sustained respiratory improvement after the transient epinephrine effect has passed.

Observe children after nebulized epinephrine for at least 2 hours; 2-4 hours is a commonly recommended post-treatment monitoring interval, and some emergency-care guidance uses 4 hours. The purpose is to identify recurrent stridor at rest or increased work of breathing after the medication effect dissipates. [6][14][18]

Discharge is appropriate after sustained clinical improvement with no stridor at rest. Children with mild symptoms and no stridor at rest can generally be discharged after dexamethasone if they remain stable. In observational outpatient cohorts treated with racemic epinephrine plus dexamethasone, children discharged after 3-4 hours of observation had no reported short-term return visits in the cited cohorts, although these data are observational. [14][18]

Admit or extend observation when moderate croup does not improve adequately within 4-6 hours after corticosteroid treatment, when repeated epinephrine is required, or when severe symptoms persist. Escalate to intensive care support when the child has an insufficient response to repeated treatment or features of respiratory failure. [5][15]
- Minimum monitored interval after epinephrine: at least 2 hours; consider 4 hours where local protocol uses a longer observation window. [6][14][18]
- Discharge threshold: no stridor at rest and sustained clinical improvement. [14][18]
- Admission trigger: persistent symptoms after 2 or more racemic epinephrine doses. [15]
- Admission trigger: inadequate improvement in moderate croup 4-6 hours after corticosteroid administration. [5]

*Post-treatment disposition decisions after dexamethasone with or without nebulized epinephrine. [5][14][15][18]*

| Disposition | Required clinical course | Treatment history | Action |
| --- | --- | --- | --- |
| Discharge | No stridor at rest and sustained improvement during observation. [14][18] | Mild disease after dexamethasone, or improved moderate disease after epinephrine and dexamethasone. [14][18] | Discharge with return precautions for recurrent stridor at rest or increased work of breathing. [14] |
| Extended emergency or observation-unit monitoring | Improvement is incomplete or recurrence risk remains uncertain after epinephrine effect wanes. [5][6] | Received nebulized epinephrine. [6][14] | Continue monitored reassessment through at least the expected duration of epinephrine effect. [5][6] |
| Hospital admission | Persistent moderate/severe symptoms, insufficient response, or recurrent obstruction. [5][15] | Symptoms after 2 or more racemic epinephrine doses or inadequate response 4-6 hours after corticosteroid. [5][15] | Provide inpatient monitoring and repeat epinephrine as clinically necessary. [5] |
| Intensive care consideration | Hypoxia, signs of impending respiratory failure, or inadequate response to treatment. [5][6] | Severe croup requiring repeated rescue therapy. [5] | Escalate airway-capable monitoring and support. [5][6] |

## Common questions

### Should oral dexamethasone be replaced with intramuscular dexamethasone in moderate croup?

No. When oral administration is tolerated, a single oral dose is effective for outpatient moderate croup and was not associated with more subsequent interventions than intramuscular dosing. Use IM or IV administration when vomiting, inability to take oral medication, or severe distress precludes the oral route. [17][21]

### Does nebulized epinephrine require hospital admission?

Not invariably. Children may be discharged after monitored observation if improvement is sustained and stridor at rest is absent; persistent symptoms, repeated epinephrine requirement, hypoxia, or inadequate response warrant extended observation or admission. [14][15][18]

## References
1. Nebulized Budesonide for Children with Mild-to-Moderate ... — www.nejm.org — https://www.nejm.org/doi/full/10.1056/NEJM199408043310501
2. A Randomized Trial of a Single Dose of Oral Dexamethasone for ... — www.nejm.org — https://www.nejm.org/doi/full/10.1056/NEJMoa033534
3. A Comparison of Nebulized Budesonide, Intramuscular ... — www.nejm.org — https://www.nejm.org/doi/full/10.1056/NEJM199808203390802
4. The assessment and management of croup — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S1526054205000886
5. Nebulized Budesonide - an overview — www.sciencedirect.com — https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/nebulized-budesonide
6. Racemic Epinephrine - an overview — www.sciencedirect.com — https://www.sciencedirect.com/topics/neuroscience/racemic-epinephrine
7. The Cochrane Library and the treatment of croup in ... — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/10.1002/ebch.613
8. Viral croup: a current perspective - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S0891524504002688
9. Finnish guidelines for the treatment of laryngitis, wheezing bronchitis ... — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/10.1111/apa.13162
10. Respiratory Infections - Clinical Virology - Wiley Online Library — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/abs/10.1128/9781555819439.ch2
11. Viral croup: Diagnosis and a treatment algorithm — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/10.1002/ppul.22993
12. Assessment and management of viral croup in children - Ovid — wchh.onlinelibrary.wiley.com — https://wchh.onlinelibrary.wiley.com/doi/pdfdirect/10.1002/psb.1490
13. Croup | Treatment summaries | BNF - NICE — bnf.nice.org.uk — https://bnf.nice.org.uk/treatment-summaries/croup
14. Clinical advances in racemic epinephrine for pediatric croup: a mini-review of evidence and practice — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC12230069
15. Croup - StatPearls - NCBI Bookshelf — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/books/NBK431070
16. The Outcome of Immediate Administration of Dexamethasone in Children With Croup (Laryngotracheobronchitis) in King Abdullah Specialized Children’s Hospital - PMC — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC9262250
17. Outpatient treatment of moderate croup with dexamethasone: intramuscular versus oral dosing. - Abstract — pubmed.ncbi.nlm.nih.gov — https://pubmed.ncbi.nlm.nih.gov/11099587
18. Common Pediatric Respiratory Emergencies — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC7132755
19. Comparison between single-dose oral prednisolone and oral dexamethasone in the treatment of croup: a randomized-controlled trial — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC10205353
20. Viral croup: diagnosis and a treatment algorithm. - Abstract — pubmed.ncbi.nlm.nih.gov — https://pubmed.ncbi.nlm.nih.gov/24596395
21. The role of corticosteroids in the treatment of croup. - Abstract — pubmed.ncbi.nlm.nih.gov — https://pubmed.ncbi.nlm.nih.gov/15219173
22. Oral dexamethasone in the treatment of croup: 0.15 mg/kg versus ... — pubmed.ncbi.nlm.nih.gov — https://pubmed.ncbi.nlm.nih.gov/8649915
23. Croup (Acute Laryngotracheobronchitis) (Chapter 352) — publications.aap.org — https://publications.aap.org/pediatriccare/book/348/chapter/5788347/Croup-Acute-Laryngotracheobronchitis-Chapter-352
24. Nebulized epinephrine for croup in children - PubMed — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/pubmed/24114291

## Editorial note

Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.